CHICAGO—In a phase 1 study in advanced non–small-cell lung cancer deemed worthy of a presentation at the American Society of Clinical Oncology’s 46th annual meeting plenary session, a multinational group of investigators reported improved survival with an oral investigational agent still unfamiliar to most oncologists.
CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented at the 2010 annual meeting of the American Society of Clinical Oncology.
CHICAGO—Denosumab delayed or prevented more skeletal-related adverse events than zoledronic acid in men with hormone-refractory prostate cancer and bone metastases.
CHICAGO—Bevacizumab in combination with chemotherapy followed by maintenance bevacizumab monotherapy improves progression-free survival (PFS) over chemotherapy alone in the treatment of advanced ovarian cancers, said Robert A. Burger, MD at the 46th American Society of Clinical Oncology annual meeting.
CHICAGO—A fentanyl pectin nasal spray provides analgesia faster than immediate-release morphine in the treatment of breakthrough cancer pain, said Andrew Davies, MD, MSc at the 46th American Society of Clinical Oncology annual meeting.
